A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.
Phase 1
Terminated
- Conditions
- HIV InfectionsInfection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 13
- Registration Number
- NCT01195974
- Locations
- πΊπΈ
GSK Investigational Site, Fargo, North Dakota, United States
Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2011-02-04
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 14
- Registration Number
- NCT01140412
- Locations
- πΈπ¬
Pfizer Investigational Site, Singapore, Singapore
Lamivudine(LAM) Good Responder Study
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Other: No intervention
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2016-09-13
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 1
- Registration Number
- NCT01128686
- Locations
- π°π·
GSK Investigational Site, Kangwon-do, Korea, Republic of
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
Phase 4
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2010-04-13
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 297
- Registration Number
- NCT01102972
- Locations
- π΅π·
GSK Investigational Site, San Juan, Puerto Rico
A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2010-04-12
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 15
- Registration Number
- NCT01101893
- Locations
- πΊπΈ
GSK Investigational Site, Buffalo, New York, United States
GSK1349572 Drug Interaction Study With Efavirenz
Phase 1
Completed
- Conditions
- Infections, Human Immunodeficiency Virus and Herpesviridae
- Interventions
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 12
- Registration Number
- NCT01098526
- Locations
- πΊπΈ
GSK Investigational Site, Buffalo, New York, United States
GSK1349572 Relative Bioavailability Study
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: GSK1349572 formulation APDrug: GSK1349572 formulation AWDrug: GSK1349572 formulation AX
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 24
- Registration Number
- NCT01098513
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
PENTA Fosamprenavir Study
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 1
- Registration Number
- NCT01077635
Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status
Completed
- Conditions
- FractureInfection, Human Immunodeficiency Virus
- Interventions
- Other: No Antiretroviral (ARV) Drug ExposureDrug: Any Antiretroviral (ARV) Drug Exposure
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 1
- Registration Number
- NCT01077557
Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency VirusHIV Infections
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2019-06-24
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 18
- Registration Number
- NCT01068925
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
Β© Copyright 2025. All Rights Reserved by MedPath